Surgery and chemotherapy have traditionally been the mainstays of treatment; however, neoadjuvant endocrine therapy (NET) has shown promise in recent years as a treatment option for patients with estrogen receptor positive (ER+) and human epidermal growth factor 2-negative (Her2–) breast cancers. The gene discussed is ESR1; the disease is breast cancer.